This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RAPT Rapt Therapeutics (RAPT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Rapt Therapeutics Stock (NASDAQ:RAPT) Get Rapt Therapeutics alerts:Sign Up Key Stats Today's Range$58.02▼$58.0250-Day Range$57.61▼$58.0252-Week Range$5.67▼$58.02VolumeN/AAverage Volume4.25 million shsMarket Capitalization$1.61 billionP/E RatioN/ADividend YieldN/APrice Target$48.44Consensus RatingHold Company Overview RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies. The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma. By selectively blocking CCR4-mediated migration of pathogenic T cells to inflamed tissues, RPT193 aims to reduce disease activity without broad immunosuppression. RAPT is also advancing discovery-stage programs against additional chemokine receptors involved in tissue inflammation, including efforts in ulcerative colitis and other indications. Since its initial public offering in 2020, RAPT has expanded its operations across the United States, leveraging partnerships and collaborations to extend its global reach. The company maintains research and development facilities in San Diego and engages with clinical sites worldwide to advance its pipeline. Under the leadership of Chief Executive Officer John C. Huggins, RAPT’s management team brings extensive experience in immunology, drug discovery and clinical development. The organization is guided by a board of directors and scientific advisors with deep expertise in translational research and biopharmaceutical innovation.AI Generated. May Contain Errors. Read More Receive RAPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rapt Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RAPT Stock News HeadlinesThis Biotech Was Quietly Bought Before a $58 Per Share TakeoutMarch 21, 2026 | fool.comRAPT Therapeutics Completes Acquisition and Transitions to Private OwnershipMarch 18, 2026 | theglobeandmail.comOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including power consumption for 1 million GPUs, a cost that rivals entire cities. That disclosure will name the supplier. One small, publicly traded power infrastructure company sits at the center of this - carrying a $1.5 billion backlog and priced like a utility. Dylan Jovine has the full breakdown.May 30 at 1:00 AM | Behind the Markets (Ad)This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per ShareMarch 15, 2026 | fool.comGSK RAPT Acquisition Adds Food Allergy Asset To Immunology Growth StoryMarch 7, 2026 | finance.yahoo.comGSK reached out to buyout target's big shareholder before talking to senior leadersMarch 5, 2026 | bizjournals.comAssessing RAPT Therapeutics (RAPT) Valuation After A Sharp 3 Month Share Price SurgeMarch 1, 2026 | finance.yahoo.comThis Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer EmergesFebruary 25, 2026 | fool.comSee More Headlines RAPT Stock Analysis - Frequently Asked Questions How were Rapt Therapeutics' earnings last quarter? Rapt Therapeutics (NASDAQ:RAPT) posted its quarterly earnings data on Thursday, November, 6th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.23. When did Rapt Therapeutics' stock split? Rapt Therapeutics's stock reverse split on the morning of Tuesday, June 17th 2025.The 1-8 reverse split was announced on Friday, June 13th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 16th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Rapt Therapeutics IPO? Rapt Therapeutics (RAPT) raised $39 million in an IPO on Thursday, October 31st 2019. The company issued 3,000,000 shares at a price of $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank acted as the underwriters for the IPO. What other stocks do shareholders of Rapt Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rapt Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD). Company Calendar Last Earnings11/06/2025Today5/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 RAPT's financial health is in the Green zone, according to TradeSmith. RAPT has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RAPT CIK1673772 Webwww.rapt.com Phone(650) 489-9000FaxN/AEmployees80Year Founded2015Price Target and Rating Average Price Target for Rapt Therapeutics$48.44 High Price Target$70.00 Low Price Target$9.00 Potential Upside/Downside-16.5%Consensus RatingHold Rating Score (0-4)2.15 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($11.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$129.87 million Net MarginsN/A Pretax MarginN/A Return on Equity-61.81% Return on Assets-54.73% Debt Debt-to-Equity RatioN/A Current Ratio12.04 Quick Ratio12.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.51 per share Price / Book5.04Miscellaneous Outstanding Shares27,711,000Free Float27,057,000Market Cap$1.61 billion OptionableOptionable Beta0.49 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:RAPT) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapt Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapt Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RAPT Stock Alerts